AML at older age: Age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance

Blood

Volumn 114, Issue 14, 2009, Pages 2869-2877

  De Jonge, Hendrik J M ^a   De Bont, Eveline S J M ^a   Valk, Peter J M ^b   Schuringa, Jan Jacob ^a   Kies, Marcel ^a   Woolthuis, Carolien M ^a   Delwel, Ruud ^b   Veeger, Nic J G M ^a   Vellenga, Edo ^a   Löwenberg, Bob ^b   Huls, Gerwin ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; FLT3 LIGAND; MESSENGER RNA; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; AGING; ARTICLE; CANCER PATIENT; CASE REPORT; COHORT ANALYSIS; CYTOGENETICS; DNA PROBE; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HIGH RISK POPULATION; HUMAN; MALE; MUTANT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE; UPREGULATION; VALIDATION STUDY;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DOWN-REGULATION; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; YOUNG ADULT;

EID: 70449475104     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-212688     Document Type: Article

References (47)

1. Shizuru JA, Negrin RS, Weissman IL. Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. Annu Rev Med. 2005;56:509-538.
2. Beghe C, Wilson A, Ershler WB. Prevalence and outcomes of anemia in geriatrics: a systematic review of the literature. Am J Med. 2004;116(suppl 7A):3S-10S. (Pubitemid 38429896)
3. Lichtman MA, Rowe JM. The relationship of patient age to the pathobiology of the clonal myeloid diseases. Semin Oncol. 2004;31(2):185-197.
4. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol. 2004;5(2):133-139. (Pubitemid 38208354)
5. Rossi DJ, Bryder D, Zahn JM, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A. 2005;102(26):9194-9199. (Pubitemid 40923540)
6. Chambers SM, Shaw CA, Gatza C, Fisk CJ, Donehower LA, Goodell MA. Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biol. 2007;5(8):1750-1762. (Pubitemid 47328278)
7. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell. 2007;130(2):223-233.
8. Rossi DJ, Jamieson CH, Weissman IL. Stems cells and the pathways to aging and cancer. Cell. 2008;132(4):681-696. (Pubitemid 351253688)
9. Krishnamurthy J, Torrice C, Ramsey MR, et al. Ink4a/Arf expression is a biomarker of aging. J Clin Invest. 2004;114(9):1299-1307.
10. Zindy F, Quelle DE, Roussel MF, Sherr CJ. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene. 1997;15(2):203-211. (Pubitemid 27344559)
11. Janzen V, Forkert R, Fleming HE, et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature. 2006(7110):443:421-426. (Pubitemid 44477274)
12. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-3485.
13. Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol. 2007;25(14):1908-1915. (Pubitemid 46854425)
14. Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108(10):3280-3288. (Pubitemid 44776864)
15. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98(5):1312-1320.
16. Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17(11):3569-3576. (Pubitemid 29517929)
17. Rowley JD, Alimena G, Garson OM, Hagemeijer A, Mitelman F, Prigogina EL. A collaborative study of the relationship of the morphological type of acute nonlymphocytic leukemia with patient age and karyotype. Blood. 1982;59(5):1013-1022.
18. Schoch C, Kern W, Krawitz P, et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood. 2001;98(12):3500.
19. Lowenberg B, Boogaerts MA, Daenen SM, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol. 1997;15(12):3496-3506. (Pubitemid 27527723)
20. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349(8):743-752. (Pubitemid 37010778)
21. Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood. 2004;103(8):2908-2913. (Pubitemid 38455431)
22. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16):1617-1628. (Pubitemid 38528701)
23. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109(9):3658-3666.
24. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003;31(4):e15.
25. Backes C, Keller A, Kuentzer J, et al. GeneTrail: advanced gene set enrichment analysis. Nucleic Acids Res. 2007;35:W186-W192.
26. Tomasson MH, Xiang Z, Walgren R, et al. Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood. 2008;111(9):4797-4808.
27. Wilson CS, Davidson GS, Martin SB, et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood. 2006;108(2):685-696.
28. Gahn B, Haase D, Unterhalt M, et al. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia. 1996;10(6):946-951. (Pubitemid 26235925)
29. Hassan HT, Rees JK. Relation between age and blast cell differentiation in acute myeloid leukaemia patients. Oncology. 1990;47(5):439-442.
30. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89(9):3323-3329. (Pubitemid 27229818)
31. Sharpless NE. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res. 2005;576(1):22-38.
32. Stirewalt DL, Choi YE, Sharpless NE, et al. Decreased IRF8 expression found in aging hematopoietic progenitor/stem cells. Leukemia. 2009;23(2):391-393.
33. Gil J, Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol. 2006;7(9):667-677. (Pubitemid 44268212)
34. Passegué E, Wagner EF. JunB suppresses cell proliferation by transcriptional activation of p16INK4a expression. EMBO J. 2000;19(12):2969- 2979. (Pubitemid 30386768)
35. Ohtani N, Zebedee Z, Huot TJG, et al. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature. 2001;409(6823):1067-1070. (Pubitemid 32204062)
36. Jacobs JJL, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999;397(6715):164-168. (Pubitemid 29050921)
37. Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity in normal and leukaemic stem cells. Nature. 2003;423(6937):255-260. (Pubitemid 40852690)
38. Park I, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003;423(6937):302-305. (Pubitemid 40852701)
39. Bracken AP, Kleine-Kohlbrecher D, Dietrich N, et al. The polycomb group proteins bind throughout the INK4A-ARf locus and are disassociated in senescent cells. Genes Dev. 2007;21(5):525-530. (Pubitemid 46409467)
40. Rizo A, Dontje B, Vellenga E, de Haan G, Schuringa JJ. Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1. Blood. 2008;111(5):2621-2630.
41. Iwama A, Oguro H, Negishi M, et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity. 2004;21(6):843-851. (Pubitemid 39626674)
42. Krug U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene. 2002;21(21):3475-3495. (Pubitemid 34587717)
43. Toyota M, Kopecky KJ, Toyota M-O, et al. Methylation profiling in AML. Blood. 2001;97(9):2823-2829.
44. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation in multiple genes in acute myeloid leukemia. Cancer Res. 1999;59(15):3730-3740. (Pubitemid 29381880)
45. Guo S-X, Taki T, Ohnishi H, et al. Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia. Leuk Res. 2000;24(1):39-46.
46. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998;12(6):845-859.
47. Zolota V, Sirinian C, Melachrinou M, Symeonidis A, Bonikos DS. Expression of the regulatory cell cycle proteins p21, p27, p14, p16, p53, mdm2 and cyclin E in bone marrow biopsies with acute myeloid leukemia: correlation with patients' survival. Pathol Res Pract. 2007;203(4):199-207. (Pubitemid 46605957)